RecruitingNCT06890377

Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy


Sponsor

Min Zhao,MD

Enrollment

90 participants

Start Date

Sep 14, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis in MSA.


Eligibility

Min Age: 35 YearsMax Age: 80 Years

Inclusion Criteria4

  • Age\> 35 years old, gender is not limited;
  • Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria;
  • all patients had been ruled out of polyQ disease by genetic testing;
  • Voluntarily participate in this study and sign the informed consent form.

Exclusion Criteria4

  • pregnancy or breastfeeding;
  • contraindications to MRI examination or inability to cooperate in completing neuroimaging examination;
  • previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above);
  • History of alcohol or drug abuse

Locations(1)

Third Xiangya Hospital of Central South University

Hunan, Changsha, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06890377


Related Trials